Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PMN
stocks logo

PMN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-4.814
+863.65%
--
--
-3.992
-24.05%
--
--
-3.992
-44.96%
Estimates Revision
The market is revising No Change the revenue expectations for ProMIS Neurosciences, Inc. (PMN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -29.02%.
EPS Estimates for FY2025
Revise Downward
down Image
-23.09%
In Past 3 Month
Stock Price
Go Down
down Image
-29.02%
In Past 3 Month
Wall Street analysts forecast PMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast PMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.630
sliders
Low
3.00
Averages
4.00
High
5.00
Current: 7.630
sliders
Low
3.00
Averages
4.00
High
5.00
Guggenheim
Eddie Hickman
Buy
downgrade
$6 -> $5
2025-11-18
Reason
Guggenheim
Eddie Hickman
Price Target
$6 -> $5
2025-11-18
downgrade
Buy
Reason
Guggenheim analyst Eddie Hickman lowered the firm's price target on ProMIS Neurosciences to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences' Alzheimer's candidate, PMN310, is rapidly advancing toward key clinical milestones, which keeps the company on track for two pivotal data readouts in 2026, the analyst tells investors following the company's Q3 report.
H.C. Wainwright
Raghuram Selvaraju
initiated
$4
2025-07-14
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$4
2025-07-14
initiated
Reason
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences with a Buy rating and $4 price target. ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.
Maxim
NULL -> Buy
initiated
$3
2025-05-12
Reason
Maxim
Price Target
$3
2025-05-12
initiated
NULL -> Buy
Reason
Maxim initiated coverage of ProMIS Neurosciences with a Buy rating and $3 price target.
Guggenheim
Eddie Hickman
Strong Buy
Reiterates
$6
2025-04-01
Reason
Guggenheim
Eddie Hickman
Price Target
$6
2025-04-01
Reiterates
Strong Buy
Reason
Guggenheim
Eddie Hickman
Strong Buy
Reiterates
n/a
2025-02-26
Reason
Guggenheim
Eddie Hickman
Price Target
n/a
2025-02-26
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for ProMIS Neurosciences Inc (PMN.O) is -0.55, compared to its 5-year average forward P/E of -1.08. For a more detailed relative valuation and DCF analysis to assess ProMIS Neurosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.08
Current PE
-0.55
Overvalued PE
0.57
Undervalued PE
-2.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.11
Undervalued EV/EBITDA
-2.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2123.33
Current PS
0.00
Overvalued PS
6499.29
Undervalued PS
-2252.64
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PMN News & Events

Events Timeline

(ET)
2025-12-01
08:50:00
H.C. Wainwright Raises ProMIS Price Target to $18 from $4
select
2025-11-24 (ET)
2025-11-24
08:23:52
ProMIS Neurosciences declares a 1-for-20 reverse stock split.
select
2025-11-12 (ET)
2025-11-12
07:15:27
ProMIS Neurosciences announces Q3 earnings per share of 24 cents, down from 31 cents a year ago.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-01Globenewswire
ProMIS Neurosciences CEO to Participate in Evercore Healthcare Conference on December 2, 2025
  • Conference Participation: ProMIS Neurosciences CEO Neil Warma will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025, showcasing the company's advancements in Alzheimer's disease treatment, which is expected to attract investor interest.
  • Product Candidate: PMN310, ProMIS's lead product candidate, is designed to selectively target toxic oligomers associated with Alzheimer's disease, potentially reducing the risk of amyloid-related imaging abnormalities and improving treatment safety and efficacy.
  • Clinical Trial Launch: Following encouraging results from initial trials, ProMIS has initiated the PRECISE-AD clinical trial to evaluate the safety and tolerability of multiple doses of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease, which is expected to provide critical data for clinical application.
  • Technology Platform: ProMIS's EpiSelect™ platform identifies toxic misfolded proteins associated with neurodegenerative diseases, facilitating the development of antibodies and vaccines targeting these specific epitopes, demonstrating the company's innovative capabilities and market potential in the biotechnology sector.
[object Object]
Preview
4.5
11-25Benzinga
Dow Rises by 300 Points; Waldencast Stock Takes a Dive

  • U.S. Stock Market Performance: U.S. stocks rose significantly, with the Nasdaq Composite gaining over 500 points, while the Dow and S&P 500 also saw increases of 0.65% and 1.40%, respectively.

  • Sector Movements: Communication services stocks surged by 3.1%, whereas consumer staples experienced a decline of 1.1%.

  • Company Highlights: Enlivex Therapeutics shares soared 48% following a major funding announcement, while Oscar Health's stock rose 21% due to potential Obamacare subsidy extensions. Conversely, Waldencast plc and Twin Hospitality Group saw significant declines in their stock prices.

  • Global Market Trends: European shares increased, with the eurozone's STOXX 600 up 0.44%, while Asian markets had mixed results, with Hong Kong's Hang Seng gaining and India's BSE Sensex declining.

[object Object]
Preview
4.5
11-24Benzinga
Nasdaq Rises by 350 Points; Enlivex Therapeutics Stock Jumps Significantly

  • U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining over 350 points, while the Dow and S&P 500 also saw increases of 0.16% and 0.83%, respectively.

  • Sector Movements: Communication services stocks rose by 2.7%, while energy stocks experienced a decline of 0.9%.

  • Company Earnings Highlights: CureVac N.V. reported better-than-expected third-quarter earnings of $1.41 per share and sales of $63.295 million, surpassing analyst estimates.

  • Market Reactions: Enlivex Therapeutics shares surged 79% following a significant private placement announcement, while Clearside Biomedical shares plummeted 67% after filing for bankruptcy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ProMIS Neurosciences Inc (PMN) stock price today?

The current price of PMN is 7.63 USD — it has increased 3.67 % in the last trading day.

arrow icon

What is ProMIS Neurosciences Inc (PMN)'s business?

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

arrow icon

What is the price predicton of PMN Stock?

Wall Street analysts forecast PMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ProMIS Neurosciences Inc (PMN)'s revenue for the last quarter?

ProMIS Neurosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is ProMIS Neurosciences Inc (PMN)'s earnings per share (EPS) for the last quarter?

ProMIS Neurosciences Inc. EPS for the last quarter amounts to -0.24 USD, decreased -177.42 % YoY.

arrow icon

What changes have occurred in the market's expectations for ProMIS Neurosciences Inc (PMN)'s fundamentals?

The market is revising No Change the revenue expectations for ProMIS Neurosciences, Inc. (PMN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -29.02%.
arrow icon

How many employees does ProMIS Neurosciences Inc (PMN). have?

ProMIS Neurosciences Inc (PMN) has 6 emplpoyees as of December 05 2025.

arrow icon

What is ProMIS Neurosciences Inc (PMN) market cap?

Today PMN has the market capitalization of 16.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free